Aptadel Therapeutics has raised two million euros to continue developing its treatment for Ewing sarcoma, a childhood cancer with a very rapid progression and a low survival rate. The biotechnology company will continue working to bring its drug to patients. The drug is capable of halting metastasis and precisely targeting the interior of tumor cells. Aptadel is awaiting the completion of studies required by regulatory agencies such as the FDA and the EMA, which will allow it to begin its first clinical trials. With the funds raised, the company, headquartered in the Barcelona Science Park (PCB), has secured the support of the Japanese consultancy Newsight Tech Angels and has also strengthened the presence of the Little Warrior Foundation. The American investor, specializing in this pediatric disease, had already invested 480,000 euros in the company. Aptadel Therapeutics is thus preparing to close a Series A funding round, with which it aims to raise nine million euros. "This funding is crucial in the context of childhood cancer, an area with a significant medical impact but limited access to private funding," explained CEO Gisela Lorente. During 2025, the biotech She also received €450,000 from the Spanish Association Against Cancer (AECC).

The Barcelona Science Park (PCB) has achieved another success. The American multinational BioIVT has acquired the Catalan company BeCytes Biotechnologies for an undisclosed sum. With this acquisition, BeCytes, which specializes in the processing of human tissues and cells for biomedical research and the pharmaceutical industry, will be able to expand its international presence and accelerate the development of new products.

The Barcelona Science Park (PCB) is completely full and has a waiting list. Spanning 100,000 square meters, the complex houses research centers, among them the German Fraunhofer Institute of Technology —one of the most important in the world, which has just set up shop there—, and companies that rent laboratories and offices to develop their products. It is a key lever for facilitating technology transfer, the great unfinished task of the Catalan research systemThe workforce of the various tenants totals 3,500 employees. Maria Terrades is the director of this infrastructure, which is part of the University of Barcelona (UB).

Packed to capacity for years, the Barcelona Science Park (PCB), part of the University of Barcelona (UB), is enjoying a boom, awaiting the future Hospital Clínic to revitalize the area as the city's main biomedical hub. The companies it houses are growing and attracting more funding, but so are the research centers that conduct research in its laboratories.

After its first edition in Granada, where Catalan participants couldn't even fill a plane, BioSpain has established itself more than twenty years later as the leading trade fair for a sector like biotechnology, which has gained ground in Spain. This year's edition is expected to surpass the record numbers from its last edition, two years ago, when more than 2,200 attendees and 1,000 companies from some thirty countries participated.

When researching, one of the most complicated steps is the industrial production of what has been validated in the laboratory. start-up Dan*na has reached this stage after a year of proving its feasibility. "In the lab, everything goes well; the challenge comes when you increase the volume because it must be technically and economically viable," summarizes the company's co-founder and CEO, Xavier Marin. Based in the Barcelona Science Park (PCB), the startup will begin producing bioplastic in large quantities, a more sustainable alternative to conventional plastics such as polypropylene or polyethylene.

SpliceBio has become the biotechnology company that has raised the most money in the history of the sector in Spain. From its laboratories in the Barcelona Science Park (PCB), the Catalan company has raised €119 million. in a financing round which will be used to validate the gene therapy he has developed for a rare disease that causes blindness. More than ten years ago, the company was born from the research conducted by Miquel Vila-Perelló and Silvia Frutos in the United States, under the leadership of Professor Tom Muir, a pioneer in protein modification that allows them to attack Stargardt disease. With a workforce of more than 40 employees, the company grew alongside the local biotechnology sector, which set another investment record this first half of the year with €227 million, according to data from Biocat.